PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 10; no. 7; p. 1365
Main Authors Majem, Margarita, Cobo, Manuel, Isla, Dolores, Marquez-Medina, Diego, Rodriguez-Abreu, Delvys, Casal-Rubio, Joaquín, Bueno, Teresa Moran, Bernabé-Caro, Reyes, Parente, Diego Pérez, Ruiz-Gracia, Pedro, Arroyo, Marta Marina, Paz-Ares, Luis
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 26.03.2021
MDPI
Subjects
Apoptosis
Biomarkers
Cancer therapies
Chemotherapy
Clinical medicine
Clinical trials
Immunotherapy
Lung cancer
Medical prognosis
Meta-analysis
Metastasis
Mutation
Oncology
Review
non-small cell lung cancer
PD-(L)1 inhibitors
first-line treatment
network meta-analysis
efficacy
immunotherapy
Online AccessGet full text

Cover

Abstract Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HR = 0.69, 95% CI: 0.52-0.90, = 0.007), overall survival (OS: HR = 0.69, 95% CI: 0.61-0.78; < 0.001) and overall response rate (ORR) (Risk ratio (RR) = 1.354, 95% CI: 1.04-1.762, = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug.
AbstractList Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HR = 0.69, 95% CI: 0.52-0.90, = 0.007), overall survival (OS: HR = 0.69, 95% CI: 0.61-0.78; < 0.001) and overall response rate (ORR) (Risk ratio (RR) = 1.354, 95% CI: 1.04-1.762, = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug.
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52–0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61–0.78; p < 0.001) and overall response rate (ORR) (Risk ratio (RR)pooled = 1.354, 95% CI: 1.04–1.762, p = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug.
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HR pooled = 0.69, 95% CI: 0.52–0.90, p = 0.007), overall survival (OS: HR pooled = 0.69, 95% CI: 0.61–0.78; p < 0.001) and overall response rate (ORR) (Risk ratio (RR) pooled = 1.354, 95% CI: 1.04–1.762, p = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug.
Author Bueno, Teresa Moran
Marquez-Medina, Diego
Cobo, Manuel
Paz-Ares, Luis
Isla, Dolores
Arroyo, Marta Marina
Rodriguez-Abreu, Delvys
Ruiz-Gracia, Pedro
Majem, Margarita
Parente, Diego Pérez
Casal-Rubio, Joaquín
Bernabé-Caro, Reyes
AuthorAffiliation 6 Medical Oncology Service, Hospital Álvaro Cunqueiro, 36213 Vigo, Spain; joaquin.casal.rubio@sergas.es
9 Medical Affairs Department, Roche Farma S.A, 28042 Madrid, Spain; diego.perez@roche.com (D.P.-P.); pedro.ruiz.pr1@roche.com (P.R.-G.); marta.marina@contractors.roche.com (M.M.A.)
1 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
5 Medical Oncology, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain; delvysra@yahoo.com
10 Medical Oncology, Hospital 12 de Octubre, 28041 Madrid, Spain; lpazaresr@seom.org
8 Medical Oncology Department, Hospital Virgen del Rocío, 41013 Seville, Spain; reyesbernab@yahoo.es
3 Medical Oncology, University Hospital Clínico Lozano Blesa, Zaragoza, 50009 IIS Aragón, Spain; lola.isla@gmail.com
4 Medical Oncology, University Hospital Miguel Servet, 50009 Zaragoza, Spain; dmarmed@hotmail.com
2 Medical Oncology, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain; manuelcobodols@yahoo.es
7 Medi
AuthorAffiliation_xml – name: 10 Medical Oncology, Hospital 12 de Octubre, 28041 Madrid, Spain; lpazaresr@seom.org
– name: 5 Medical Oncology, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain; delvysra@yahoo.com
– name: 7 Medical Oncology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain; mmoran@iconcologia.net
– name: 6 Medical Oncology Service, Hospital Álvaro Cunqueiro, 36213 Vigo, Spain; joaquin.casal.rubio@sergas.es
– name: 4 Medical Oncology, University Hospital Miguel Servet, 50009 Zaragoza, Spain; dmarmed@hotmail.com
– name: 9 Medical Affairs Department, Roche Farma S.A, 28042 Madrid, Spain; diego.perez@roche.com (D.P.-P.); pedro.ruiz.pr1@roche.com (P.R.-G.); marta.marina@contractors.roche.com (M.M.A.)
– name: 2 Medical Oncology, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain; manuelcobodols@yahoo.es
– name: 1 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
– name: 8 Medical Oncology Department, Hospital Virgen del Rocío, 41013 Seville, Spain; reyesbernab@yahoo.es
– name: 3 Medical Oncology, University Hospital Clínico Lozano Blesa, Zaragoza, 50009 IIS Aragón, Spain; lola.isla@gmail.com
Author_xml – sequence: 1
  givenname: Margarita
  orcidid: 0000-0002-9919-7485
  surname: Majem
  fullname: Majem, Margarita
  organization: Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
– sequence: 2
  givenname: Manuel
  orcidid: 0000-0003-3402-1144
  surname: Cobo
  fullname: Cobo, Manuel
  organization: Medical Oncology, Hospital Regional Universitario de Málaga, 29010 Malaga, Spain
– sequence: 3
  givenname: Dolores
  orcidid: 0000-0002-2483-198X
  surname: Isla
  fullname: Isla, Dolores
  organization: Medical Oncology, University Hospital Clínico Lozano Blesa, IIS Aragon, 50009 Zaragoza, Spain
– sequence: 4
  givenname: Diego
  surname: Marquez-Medina
  fullname: Marquez-Medina, Diego
  organization: Medical Oncology, University Hospital Miguel Servet, 50009 Zaragoza, Spain
– sequence: 5
  givenname: Delvys
  surname: Rodriguez-Abreu
  fullname: Rodriguez-Abreu, Delvys
  organization: Medical Oncology, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain
– sequence: 6
  givenname: Joaquín
  surname: Casal-Rubio
  fullname: Casal-Rubio, Joaquín
  organization: Medical Oncology Service, Hospital Álvaro Cunqueiro, 36213 Vigo, Spain
– sequence: 7
  givenname: Teresa Moran
  surname: Bueno
  fullname: Bueno, Teresa Moran
  organization: Medical Oncology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
– sequence: 8
  givenname: Reyes
  surname: Bernabé-Caro
  fullname: Bernabé-Caro, Reyes
  organization: Medical Oncology Department, Hospital Virgen del Rocío, 41013 Seville, Spain
– sequence: 9
  givenname: Diego Pérez
  surname: Parente
  fullname: Parente, Diego Pérez
  organization: Medical Affairs Department, Roche Farma S.A, 28042 Madrid, Spain
– sequence: 10
  givenname: Pedro
  surname: Ruiz-Gracia
  fullname: Ruiz-Gracia, Pedro
  organization: Medical Affairs Department, Roche Farma S.A, 28042 Madrid, Spain
– sequence: 11
  givenname: Marta Marina
  surname: Arroyo
  fullname: Arroyo, Marta Marina
  organization: Medical Affairs Department, Roche Farma S.A, 28042 Madrid, Spain
– sequence: 12
  givenname: Luis
  surname: Paz-Ares
  fullname: Paz-Ares, Luis
  organization: Medical Oncology, Hospital 12 de Octubre, 28041 Madrid, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33810441$$D View this record in MEDLINE/PubMed
BookMark eNpdkU9v1DAQxS1URP_QE3c0EpciFLDjJHY4IK2WllZKSyXKOXKSycZLYi-207IfhW-Lq5ZqwZcZaX56fjPvkOwZa5CQV4y-57ykH9btxCgVjBf5M3KQUiESyiXf2-n3ybH3axqflFnKxAuyz7lkNMvYAfl9_Tk5qd4yuDCDbnSwzoPycGmNDQM6tdlCbx3EHs608yGptEG4cajChCaA7eHKmuTbpMYxWeI4QjWbFSyVadHBtQo6Uh7udBjgXK8GiP9VDE5_bRx6r635CAu4wnBn3Q-4xKCShVHj1mv_kjzv1ejx-LEeke9npzfL86T6-uViuaiSNqNlSNq2K5RIVSPLomt6mnWyb3hTUN7xkqVdkRUNyg6xY5iXoozTnHKUaZ-XnUglPyKfHnQ3czNh10a_To31xulJuW1tla7_nRg91Ct7W0vKC5lnUeDkUcDZnzP6UE_at_EUyqCdfZ3mVOaF4IxF9M1_6NrOLi4cqSKLkfBM3Dt690C1znrvsH8yw2h9n3q9k3qkX-_6f2L_Zsz_AG5KqcQ
CitedBy_id crossref_primary_10_1186_s12885_023_11366_4
crossref_primary_10_3389_fonc_2024_1365255
crossref_primary_10_3390_jcm12155063
crossref_primary_10_1186_s12885_023_10959_3
crossref_primary_10_3389_fonc_2023_1137913
crossref_primary_10_1177_17588359221105024
crossref_primary_10_1016_j_intimp_2022_108985
crossref_primary_10_3390_jcm10194583
crossref_primary_10_1016_j_critrevonc_2022_103806
crossref_primary_10_1186_s12962_023_00417_z
crossref_primary_10_1016_j_hoc_2023_02_008
crossref_primary_10_3390_cancers14246250
Cites_doi 10.1080/2162402X.2020.1746112
10.1016/j.annonc.2020.08.2284
10.1038/bjc.2014.555
10.1016/j.cllc.2020.10.002
10.1016/j.jtho.2019.08.427
10.1016/S0140-6736(19)32222-6
10.1016/S1470-2045(18)30261-4
10.1016/S0140-6736(16)00587-0
10.1002/path.5344
10.1097/COC.0000000000000239
10.1097/XEB.0000000000000140
10.1056/NEJMoa1606774
10.1016/j.jtho.2018.04.039
10.1016/j.lungcan.2015.06.005
10.1158/2326-6066.CIR-18-0214
10.1038/s41591-018-0134-3
10.1056/NEJMoa1917346
10.1155/2018/3820956
10.3322/caac.21492
10.1016/S0895-4356(97)00049-8
10.1200/JCO.2020.38.15_suppl.9501
10.1200/JCO.18.00149
10.1016/j.lungcan.2016.05.001
10.1016/j.jclinepi.2009.06.005
10.1136/esmoopen-2018-000406
10.1016/j.ejca.2015.11.016
10.1136/esmoopen-2016-000083
10.3389/fonc.2019.00972
10.3390/jcm9072093
10.21037/atm.2017.06.48
10.1038/modpathol.2015.63
10.1093/annonc/mdy275
10.1016/S0140-6736(18)32409-7
10.1056/NEJMoa1709937
10.1056/NEJMoa1810865
10.1111/1759-7714.13681
10.1158/1078-0432.CCR-15-3101
10.1055/s-0036-1592337
10.21037/tlcr-19-638
10.1056/NEJMoa1801946
10.1016/S1470-2045(19)30407-3
10.1177/030089161209800612
10.1016/j.jtho.2016.06.006
10.1200/EDBK_201435
10.1016/j.lungcan.2017.11.017
10.1093/annonc/mdz288
10.1093/annonc/mdz394.078
10.1016/j.lungcan.2015.05.007
10.21037/tlcr-20-192
10.7150/jca.22361
10.1016/j.lungcan.2020.04.027
10.1097/MD.0000000000004611
10.21037/tlcr.2019.08.04
10.1093/annonc/mdy424.067
10.1200/JCO.19.00934
10.1056/NEJMoa1716948
10.1056/NEJMoa1507643
10.1016/j.cllc.2018.01.002
10.1016/j.ccell.2018.03.018
10.1016/S0140-6736(21)00228-2
10.1200/JCO.2012.47.1102
10.1093/annonc/mdz394.081
10.1093/annonc/mdz394.077
10.1016/S0140-6736(16)32517-X
10.1093/annonc/mdy292.124
10.1158/1538-7445.AM2017-CT082
10.1200/JCO.2017.35.15_suppl.9090
10.1200/JCO.18.01042
10.1056/NEJMoa1809064
10.1038/nature12477
10.1158/1078-0432.CCR-14-2959
10.1002/jgm.3294
10.2217/imt-2018-0198
10.1016/j.jtho.2015.09.009
10.1001/jamaoncol.2020.0237
10.1093/annonc/mdx380
10.1158/1078-0432.CCR-12-1362
10.1056/NEJMoa1501824
10.1056/NEJMoa1613493
10.1056/NEJMc1713444
10.1093/annonc/mdz063
10.21037/tlcr.2018.10.08
10.1016/j.jtho.2019.08.486
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.3390/jcm10071365
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest - Health & Medical Complete保健、医学与药学数据库
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X7
  name: Health & Medical Complete (ProQuest Database)
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2077-0383
ExternalDocumentID 10_3390_jcm10071365
33810441
Genre Journal Article
Review
GrantInformation_xml – fundername: Roche
  grantid: NA
GroupedDBID 53G
5VS
7X7
8FI
8FJ
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
DIK
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
ITC
KQ8
M48
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
RPM
UKHRP
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c409t-ccd6a72ab896dbf04d8fb3b603d3912d646be8deed1e59798fb503e82f59d7283
IEDL.DBID RPM
ISSN 2077-0383
IngestDate Tue Sep 17 21:17:32 EDT 2024
Sat Oct 26 06:00:28 EDT 2024
Thu Oct 10 19:20:25 EDT 2024
Tue Oct 29 04:03:12 EDT 2024
Sat Nov 02 12:23:23 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords non-small cell lung cancer
PD-(L)1 inhibitors
first-line treatment
network meta-analysis
efficacy
immunotherapy
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c409t-ccd6a72ab896dbf04d8fb3b603d3912d646be8deed1e59798fb503e82f59d7283
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-9919-7485
0000-0002-2483-198X
0000-0003-3402-1144
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036854/
PMID 33810441
PQID 2641043478
PQPubID 5046890
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8036854
proquest_miscellaneous_2508567311
proquest_journals_2641043478
crossref_primary_10_3390_jcm10071365
pubmed_primary_33810441
PublicationCentury 2000
PublicationDate 20210326
PublicationDateYYYYMMDD 2021-03-26
PublicationDate_xml – month: 3
  year: 2021
  text: 20210326
  day: 26
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Journal of clinical medicine
PublicationTitleAlternate J Clin Med
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Luft (ref_57) 2018; 379
ref_53
Conforti (ref_59) 2018; 19
Greillier (ref_42) 2018; 7
Andreozzi (ref_20) 2015; 112
Mok (ref_33) 2019; 393
Ready (ref_46) 2019; 37
Gainor (ref_73) 2016; 22
Maggio (ref_71) 2020; 145
Crama (ref_70) 2020; 11
Antonia (ref_8) 2017; 377
Dediu (ref_4) 2013; 31
Cha (ref_17) 2016; 97
Koh (ref_24) 2015; 28
Hellmann (ref_45) 2018; 33
Huang (ref_7) 2019; 9
Sezer (ref_37) 2021; 397
Fehrenbacher (ref_27) 2018; 13
Alexandrov (ref_39) 2013; 500
Takada (ref_26) 2016; 11
You (ref_61) 2018; 9
Fehrenbacher (ref_79) 2016; 387
Zhou (ref_63) 2016; 95
Goldstraw (ref_3) 2016; 11
Antonia (ref_29) 2019; 20
Liu (ref_66) 2020; 9
Khunger (ref_6) 2018; 19
Alborelli (ref_38) 2020; 250
Kanesvaran (ref_69) 2018; 38
Bray (ref_1) 2018; 68
Thakur (ref_21) 2016; 37
Herbst (ref_28) 2017; 35
Zhao (ref_62) 2018; 2018
Kim (ref_82) 2018; 29
Socinski (ref_47) 2019; 30
Aguilar (ref_77) 2019; 30
Herbst (ref_81) 2019; 30
Garassino (ref_50) 2019; 14
Garon (ref_11) 2019; 37
Dvorkin (ref_10) 2019; 394
Tuminello (ref_25) 2020; 9
Chen (ref_14) 2012; 18
Hellmann (ref_44) 2018; 378
Planchard (ref_2) 2018; 29
Norum (ref_75) 2018; 3
Langer (ref_83) 2019; 30
ref_30
Tan (ref_60) 2018; 115
Horn (ref_9) 2018; 379
Gandara (ref_48) 2018; 24
Michot (ref_76) 2016; 54
Reck (ref_58) 2020; 38
Chen (ref_18) 2012; 98
Zhou (ref_67) 2015; 4
Rittmeyer (ref_80) 2017; 389
Liang (ref_5) 2020; 9
Gettinger (ref_43) 2018; 29
Tray (ref_64) 2018; 6
Reck (ref_13) 2019; 37
Doi (ref_51) 2018; 16
Gettinger (ref_12) 2019; 14
Igarashi (ref_22) 2016; 1
Yarchoan (ref_40) 2017; 377
Moher (ref_54) 2009; 62
Borghaei (ref_72) 2015; 373
Rossi (ref_68) 2019; 11
Bucher (ref_52) 1997; 50
Carbone (ref_35) 2017; 376
Takeyasu (ref_78) 2020; 22
Buchbinder (ref_16) 2016; 39
Brahmer (ref_32) 2020; 31
Cooper (ref_19) 2015; 89
Socinski (ref_56) 2018; 378
ref_84
Dong (ref_41) 2020; 23
Garon (ref_74) 2015; 372
Voong (ref_65) 2017; 5
Reck (ref_31) 2016; 375
Rizvi (ref_36) 2020; 6
Gandara (ref_49) 2017; 28
Mok (ref_55) 2019; 30
Soria (ref_15) 2015; 21
Huijuan (ref_23) 2019; 8
Herbst (ref_34) 2020; 383
References_xml – volume: 9
  start-page: 1746112
  year: 2020
  ident: ref_66
  article-title: Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: A systematic review and network meta-analysis
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1746112
  contributor:
    fullname: Liu
– volume: 31
  start-page: S1181
  year: 2020
  ident: ref_32
  article-title: LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs. platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.08.2284
  contributor:
    fullname: Brahmer
– volume: 112
  start-page: 95
  year: 2015
  ident: ref_20
  article-title: PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
  publication-title: Br. J. Cancer.
  doi: 10.1038/bjc.2014.555
  contributor:
    fullname: Andreozzi
– volume: 22
  start-page: 127
  year: 2020
  ident: ref_78
  article-title: Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2020.10.002
  contributor:
    fullname: Takeyasu
– volume: 14
  start-page: S216
  year: 2019
  ident: ref_50
  article-title: OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for Nonsquamous NSCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.08.427
  contributor:
    fullname: Garassino
– volume: 394
  start-page: 1929
  year: 2019
  ident: ref_10
  article-title: Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32222-6
  contributor:
    fullname: Dvorkin
– volume: 19
  start-page: 737
  year: 2018
  ident: ref_59
  article-title: Cancer immunotherapy efficacy and patients’ sex: A systematic review and meta-analysis
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30261-4
  contributor:
    fullname: Conforti
– volume: 387
  start-page: 1837
  year: 2016
  ident: ref_79
  article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00587-0
  contributor:
    fullname: Fehrenbacher
– volume: 250
  start-page: 19
  year: 2020
  ident: ref_38
  article-title: Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
  publication-title: J. Pathol.
  doi: 10.1002/path.5344
  contributor:
    fullname: Alborelli
– volume: 39
  start-page: 98
  year: 2016
  ident: ref_16
  article-title: CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
  publication-title: Am. J. Clin. Oncol.
  doi: 10.1097/COC.0000000000000239
  contributor:
    fullname: Buchbinder
– volume: 16
  start-page: 187
  year: 2018
  ident: ref_51
  article-title: A generalized pairwise modelling framework for network meta-analysis
  publication-title: Int. J. Evid. Based Healthc.
  doi: 10.1097/XEB.0000000000000140
  contributor:
    fullname: Doi
– volume: 375
  start-page: 1823
  year: 2016
  ident: ref_31
  article-title: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606774
  contributor:
    fullname: Reck
– volume: 13
  start-page: 1156
  year: 2018
  ident: ref_27
  article-title: Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2018.04.039
  contributor:
    fullname: Fehrenbacher
– volume: 4
  start-page: 203
  year: 2015
  ident: ref_67
  article-title: PD-L1 over-expression and survival in patients with non-small cell lung cancer: A meta-analysis
  publication-title: Transl. Lung Cancer Res.
  doi: 10.1016/j.lungcan.2015.06.005
  contributor:
    fullname: Zhou
– volume: 6
  start-page: 1122
  year: 2018
  ident: ref_64
  article-title: Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0214
  contributor:
    fullname: Tray
– volume: 24
  start-page: 1441
  year: 2018
  ident: ref_48
  article-title: Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0134-3
  contributor:
    fullname: Gandara
– volume: 383
  start-page: 1328
  year: 2020
  ident: ref_34
  article-title: Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1917346
  contributor:
    fullname: Herbst
– volume: 2018
  start-page: 3820956
  year: 2018
  ident: ref_62
  article-title: Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
  publication-title: BioMed Res. Int.
  doi: 10.1155/2018/3820956
  contributor:
    fullname: Zhao
– volume: 68
  start-page: 394
  year: 2018
  ident: ref_1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
  contributor:
    fullname: Bray
– volume: 50
  start-page: 683
  year: 1997
  ident: ref_52
  article-title: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/S0895-4356(97)00049-8
  contributor:
    fullname: Bucher
– volume: 38
  start-page: 9501
  year: 2020
  ident: ref_58
  article-title: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs. 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.15_suppl.9501
  contributor:
    fullname: Reck
– volume: 37
  start-page: 537
  year: 2019
  ident: ref_13
  article-title: Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.00149
  contributor:
    fullname: Reck
– volume: 97
  start-page: 73
  year: 2016
  ident: ref_17
  article-title: Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2016.05.001
  contributor:
    fullname: Cha
– volume: 62
  start-page: 1006
  year: 2009
  ident: ref_54
  article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/j.jclinepi.2009.06.005
  contributor:
    fullname: Moher
– volume: 3
  start-page: e000406
  year: 2018
  ident: ref_75
  article-title: Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): A review of the literature
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2018-000406
  contributor:
    fullname: Norum
– volume: 54
  start-page: 139
  year: 2016
  ident: ref_76
  article-title: Immune-related adverse events with immune checkpoint blockade: A comprehensive review
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2015.11.016
  contributor:
    fullname: Michot
– volume: 1
  start-page: e000083
  year: 2016
  ident: ref_22
  article-title: Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2016-000083
  contributor:
    fullname: Igarashi
– volume: 9
  start-page: 972
  year: 2019
  ident: ref_7
  article-title: Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.00972
  contributor:
    fullname: Huang
– ident: ref_30
  doi: 10.3390/jcm9072093
– volume: 5
  start-page: 376
  year: 2017
  ident: ref_65
  article-title: Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm.2017.06.48
  contributor:
    fullname: Voong
– volume: 28
  start-page: 1154
  year: 2015
  ident: ref_24
  article-title: Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: Comparison with histology and driver oncogenic alteration status
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2015.63
  contributor:
    fullname: Koh
– volume: 29
  start-page: iv192
  year: 2018
  ident: ref_2
  article-title: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy275
  contributor:
    fullname: Planchard
– volume: 393
  start-page: 1819
  year: 2019
  ident: ref_33
  article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)32409-7
  contributor:
    fullname: Mok
– volume: 377
  start-page: 1919
  year: 2017
  ident: ref_8
  article-title: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1709937
  contributor:
    fullname: Antonia
– volume: 379
  start-page: 2040
  year: 2018
  ident: ref_57
  article-title: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1810865
  contributor:
    fullname: Luft
– volume: 11
  start-page: 3357
  year: 2020
  ident: ref_70
  article-title: Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.13681
  contributor:
    fullname: Crama
– volume: 22
  start-page: 4585
  year: 2016
  ident: ref_73
  article-title: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-3101
  contributor:
    fullname: Gainor
– volume: 37
  start-page: 760
  year: 2016
  ident: ref_21
  article-title: Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer
  publication-title: Semin. Respir. Crit. Care Med.
  doi: 10.1055/s-0036-1592337
  contributor:
    fullname: Thakur
– volume: 9
  start-page: 1343
  year: 2020
  ident: ref_25
  article-title: PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: A meta-analysis
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr-19-638
  contributor:
    fullname: Tuminello
– volume: 378
  start-page: 2093
  year: 2018
  ident: ref_44
  article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1801946
  contributor:
    fullname: Hellmann
– volume: 20
  start-page: 1395
  year: 2019
  ident: ref_29
  article-title: Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: A pooled analysis
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30407-3
  contributor:
    fullname: Antonia
– volume: 98
  start-page: 751
  year: 2012
  ident: ref_18
  article-title: Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
  publication-title: Tumori J.
  doi: 10.1177/030089161209800612
  contributor:
    fullname: Chen
– volume: 11
  start-page: 1879
  year: 2016
  ident: ref_26
  article-title: Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2016.06.006
  contributor:
    fullname: Takada
– volume: 38
  start-page: 400
  year: 2018
  ident: ref_69
  article-title: Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research
  publication-title: Am. Soc. Clin. Oncol. Educ. Book
  doi: 10.1200/EDBK_201435
  contributor:
    fullname: Kanesvaran
– volume: 115
  start-page: 84
  year: 2018
  ident: ref_60
  article-title: Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer—A systematic review and network meta-analysis of 3024 participants
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.11.017
  contributor:
    fullname: Tan
– volume: 30
  start-page: 1653
  year: 2019
  ident: ref_77
  article-title: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz288
  contributor:
    fullname: Aguilar
– volume: 30
  start-page: v917
  year: 2019
  ident: ref_83
  article-title: Abstract LBA80-Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz394.078
  contributor:
    fullname: Langer
– volume: 89
  start-page: 181
  year: 2015
  ident: ref_19
  article-title: PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2015.05.007
  contributor:
    fullname: Cooper
– ident: ref_53
– volume: 9
  start-page: 1302
  year: 2020
  ident: ref_5
  article-title: Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: A Bayesian analysis
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr-20-192
  contributor:
    fullname: Liang
– volume: 9
  start-page: 1200
  year: 2018
  ident: ref_61
  article-title: A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
  publication-title: J. Cancer
  doi: 10.7150/jca.22361
  contributor:
    fullname: You
– volume: 145
  start-page: 95
  year: 2020
  ident: ref_71
  article-title: ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.04.027
  contributor:
    fullname: Maggio
– volume: 95
  start-page: e4611
  year: 2016
  ident: ref_63
  article-title: Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
  publication-title: Medicine
  doi: 10.1097/MD.0000000000004611
  contributor:
    fullname: Zhou
– volume: 8
  start-page: 429
  year: 2019
  ident: ref_23
  article-title: The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: A meta-analysis of 50 studies with 11,383 patients
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr.2019.08.04
  contributor:
    fullname: Huijuan
– volume: 29
  start-page: viii744
  year: 2018
  ident: ref_82
  article-title: Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy424.067
  contributor:
    fullname: Kim
– volume: 37
  start-page: 2518
  year: 2019
  ident: ref_11
  article-title: Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.00934
  contributor:
    fullname: Garon
– volume: 378
  start-page: 2288
  year: 2018
  ident: ref_56
  article-title: Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1716948
  contributor:
    fullname: Socinski
– volume: 373
  start-page: 1627
  year: 2015
  ident: ref_72
  article-title: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1507643
  contributor:
    fullname: Borghaei
– volume: 19
  start-page: e335
  year: 2018
  ident: ref_6
  article-title: Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2018.01.002
  contributor:
    fullname: Khunger
– volume: 33
  start-page: 843
  year: 2018
  ident: ref_45
  article-title: Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccell.2018.03.018
  contributor:
    fullname: Hellmann
– volume: 397
  start-page: 592
  year: 2021
  ident: ref_37
  article-title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00228-2
  contributor:
    fullname: Sezer
– volume: 31
  start-page: 2895
  year: 2013
  ident: ref_4
  article-title: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.47.1102
  contributor:
    fullname: Dediu
– volume: 30
  start-page: v919
  year: 2019
  ident: ref_47
  article-title: LBA83-Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz394.081
  contributor:
    fullname: Socinski
– volume: 30
  start-page: v916
  year: 2019
  ident: ref_81
  article-title: Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz394.077
  contributor:
    fullname: Herbst
– volume: 389
  start-page: 255
  year: 2017
  ident: ref_80
  article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32517-X
  contributor:
    fullname: Rittmeyer
– volume: 29
  start-page: viii544
  year: 2018
  ident: ref_43
  article-title: CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy292.124
  contributor:
    fullname: Gettinger
– ident: ref_84
  doi: 10.1158/1538-7445.AM2017-CT082
– volume: 35
  start-page: 9090
  year: 2017
  ident: ref_28
  article-title: Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.9090
  contributor:
    fullname: Herbst
– volume: 37
  start-page: 992
  year: 2019
  ident: ref_46
  article-title: First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.01042
  contributor:
    fullname: Ready
– volume: 379
  start-page: 2220
  year: 2018
  ident: ref_9
  article-title: First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809064
  contributor:
    fullname: Horn
– volume: 500
  start-page: 415
  year: 2013
  ident: ref_39
  article-title: Signatures of mutational processes in human cancer
  publication-title: Nature
  doi: 10.1038/nature12477
  contributor:
    fullname: Alexandrov
– volume: 21
  start-page: 2256
  year: 2015
  ident: ref_15
  article-title: Immune checkpoint modulation for non-small cell lung cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-2959
  contributor:
    fullname: Soria
– volume: 23
  start-page: e3294
  year: 2020
  ident: ref_41
  article-title: PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
  publication-title: J. Gene Med.
  doi: 10.1002/jgm.3294
  contributor:
    fullname: Dong
– volume: 11
  start-page: 921
  year: 2019
  ident: ref_68
  article-title: PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis
  publication-title: Immunotherapy
  doi: 10.2217/imt-2018-0198
  contributor:
    fullname: Rossi
– volume: 11
  start-page: 39
  year: 2016
  ident: ref_3
  article-title: The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2015.09.009
  contributor:
    fullname: Goldstraw
– volume: 6
  start-page: 661
  year: 2020
  ident: ref_36
  article-title: Durvalumab With or Without Tremelimumab vs. Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2020.0237
  contributor:
    fullname: Rizvi
– volume: 28
  start-page: v460
  year: 2017
  ident: ref_49
  article-title: 1295O-Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx380
  contributor:
    fullname: Gandara
– volume: 18
  start-page: 6580
  year: 2012
  ident: ref_14
  article-title: Molecular pathways: Next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-1362
  contributor:
    fullname: Chen
– volume: 372
  start-page: 2018
  year: 2015
  ident: ref_74
  article-title: Pembrolizumab for the treatment of non-small-cell lung cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1501824
  contributor:
    fullname: Garon
– volume: 376
  start-page: 2415
  year: 2017
  ident: ref_35
  article-title: First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1613493
  contributor:
    fullname: Carbone
– volume: 377
  start-page: 2500
  year: 2017
  ident: ref_40
  article-title: Tumor Mutational Burden and Response Rate to PD-1 Inhibition
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1713444
  contributor:
    fullname: Yarchoan
– volume: 30
  start-page: i38
  year: 2019
  ident: ref_55
  article-title: Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz063
  contributor:
    fullname: Mok
– volume: 7
  start-page: 639
  year: 2018
  ident: ref_42
  article-title: The clinical utility of tumor mutational burden in non-small cell lung cancer
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr.2018.10.08
  contributor:
    fullname: Greillier
– volume: 14
  start-page: S244
  year: 2019
  ident: ref_12
  article-title: OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs. Docetaxel in Previously Treated NSCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.08.486
  contributor:
    fullname: Gettinger
SSID ssj0000884217
Score 2.2871451
SecondaryResourceType review_article
Snippet Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 1365
SubjectTerms Apoptosis
Biomarkers
Cancer therapies
Chemotherapy
Clinical medicine
Clinical trials
Immunotherapy
Lung cancer
Medical prognosis
Meta-analysis
Metastasis
Mutation
Oncology
Review
SummonAdditionalLinks – databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFLWgkxAviG-yDXSR9gAP1hzbcRJe0CitBuqqCjZpb5G_ohV1yVg7CX4K_5brxikdSLxFshVHOb6-59rH9xJygKDamglHuVSeSmVLapjgaPGeGXSXytm1QHaqjs_k5_PsPG64LaOssl8T1wu1a23YIz9Ex42Rg5B58f7qOw1Vo8LpaiyhcZfscIwU2IDsfBhNZ182uyxoQxJJd3cxT2B8f_jNXqbr0Cy4k21X9A-__FsmueV3xg_Jg0gY4ahD-BG545vH5N5JPBJ_Qn7NPtI3k7cpfGou5mYeiueAXgLaarxb9ROQlwI-w3iOVI9i9OnhtNeXQ1vDtG3o10u9WNChXyxggvYPwzAbrmHWpV1dQtivhSAKARxvksLoR1TQNu_gCKadmBxO_ErTPs_JU3I2Hp0Oj2mst0AtRnkraq1TOufaFKVypmbSFbURRiGUoky5U1IZXzj0qqnHOKTE1owJX_A6K12OPOUZGTRt418Q4GXBbK4yJ6WWtVH4GmRKMjVKayFYmZCD_tdXV11ajQrDkYBQtYVQQvZ7WKpoW8vqz0xIyOtNM1pFOOrQjW9vsA_yzkzlIk0T8rxDcTOOCEnNkAUmJL-F76ZDyLh9u6WZX6wzbxcs5OuXu___rD1ynwflCxOUq30yWF3f-JdIXVbmVZyfvwHVsO_n
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Na9wwEBVpCqWX0vQrbpMyhRzag1pZkmW5EELYZknLZgk0C7kZyZLJFsfb7m4g-Sn9tx35Y8kmOfRmkGyBnkbznjWaIWQPQS1KJhzlUnkqVZFRywRHi_fMortUrmgCZMfqeCJ_nCfnG6QvxtlN4OJBaRfqSU3m1efrPzcHaPD7QXGiZP_yq7iMG7WlkkfkMZco0UMMX8fzmy1Za8mb6rucpSllKMvau3p331_3Tvco593IyVuuaPicPOs4JBy2oG-RDV-_IE9OulPyl-Tv6Tf6cfQphu_1xdROQz0dMAtA8-2uW90AUlXAZxhOkf1RFKQezvqQc5iVMJ7V9OelqSo68FUFI9wSYBAWyBxO20ysCwi_cCHEiQCON4rh6LoLqq2_wiGM2_hyOPFLQ_vUJ6_IZHh0NjimXQkGWqDwW9KicMqk3FidKWdLJp0urbAK0RVZzJ2Synrt0NHGHqVJhq0JE17zMslcitTlNdmsZ7XfJsAzzYpUJU5KI0ur8DNInmRslTGIWBaRvX7q899tpo0cFUpAKL-FUER2eljyfrXkyOpQVgqZ6oh8WDWjoYTTD1P72RX2QSqaqFTEcUTetCiuxhEhzxkSw4ika_iuOoQk3Ost9fSiScatWUjhL9_-x7jvyFMeImKYoFztkM3l_MrvIqVZ2vfNcv0HC2j0nw
  priority: 102
  providerName: Scholars Portal
Title PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/33810441
https://www.proquest.com/docview/2641043478
https://search.proquest.com/docview/2508567311
https://pubmed.ncbi.nlm.nih.gov/PMC8036854
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED5tQ0K8IH4vY1SHtAd48JrEjuPwNkqrgdqqgk3qWxU7jhaUptPaSeNP4b_lnB9VC2-8JbITR_nuct_Fn88AZwSqyX2esVBIy4Q0CdM-D8njra8pXMrM1ALZqby8Ft_m0fwAom4tTC3aN7o4r8rleVXc1NrK26Xpdzqx_mwyUL4rmy76h3BIBrqTotefX6UE8exmLR6nlL7_0yyDOhuTbp8a7mpaCRHsB6J_2OXfIsmdqDN6Bk9buogXzWM9hwNbvYDHk3ZC_CX8nn1hH8YfA_xa3RS6cFvnYLpG8tR2ZdUvJFaKdIyjgogeo9zT4lWnLsdVjtNVxX4s07JkA1uWOCbvx4GzhTucNUVX1-j-1qKThCCNNw5w-NDqZ6tPeIHTRkqOE7tJWVfl5BVcj4ZXg0vW7rbADOV4G2ZMJtM4TLVKZKZzX2Qq11xLApInQZhJIbVVGcXUwFIWklBr5HOrwjxKsphYyms4qlaVPQYME-WbWEaZEKnItaTbEE8SgZZpyrmfeHDWvfrFbVNUY0HJiANrsQOWB6cdLIvWs9YLInAEHxex8uD9tpl8wk10pJVd3VMfYp2RjHkQePCmQXE7Tge_B_EevtsOrt72fguZYV13uzW7k_--8i08CZ0kxucslKdwtLm7t--I02x0jyx5Hvfg0efhdPadziZC9Wq7_gNQcfrd
link.rule.ids 230,315,730,783,787,888,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgk4AXxG8yBhzSHuDBmhM7TsILGqVVB2lUQSftLbJjRyvqkm3tJPhT-G85N07pQOItkq04yvl832d_viPkAI1a1YwbGglpqZBVRjXjEXq8ZRrDpTTVWiBbyPGJ-Hwan_oNt6WXVfZr4nqhNm3l9sgPMXAjc-AiST9cXFJXNcqdrvoSGrfJrktVheRr9-OwmH7d7LKgDwkE3d3FPI78_vB7dR6uqZkLJ9uh6B98-bdMcivujB6Q-x4wwlFn4Yfklm0ekTsTfyT-mPyafqJv83chHDdncz13xXNALQF91d-t-gmISwGfYTRHqEeRfVqY9fpyaGso2oZ-O1eLBR3YxQJy9H8YuNlwBdMu7eoS3H4tOFEI4Hh5CMMfXkHbvIcjKDoxOUzsStE-z8kTcjIazgZj6ust0ApZ3opWlZEqiZROM2l0zYRJa821RFPyLIyMFFLb1GBUDS3ykAxbY8ZtGtVxZhLEKU_JTtM29jmBKEtZlcjYCKFErSW-BpGSCLVUinOWBeSg__XlRZdWo0Q64ixUblkoIPu9WUrvW8vyz0wIyJtNM3qFO-pQjW2vsQ_izlgmPAwD8qyz4mYc7pKaIQoMSHLDvpsOLuP2zZZmfrbOvJ0yl69f7P3_s16Tu-PZJC_z4-LLC3IvcioYxmkk98nO6uravkQYs9Kv_Fz9DV_p8uE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwED5BJ028IMavBTY4pD3Ag1UndpyEFzS6Vht0UQWbtLcojh2tqEvG2knwp_Dfcm7c0oHEWyRbcZTvzved_fkMcECgVjUXhkVSWSZVlTHNRUQeb7mmcKlMtRTI5ur4XH66iC-8_mnuZZWrOXE5UZu2cmvkfQrclDkImaT92ssiJkejD9ffmbtByu20-us07sNWIpXgPdj6OMwnX9YrLuRPkgh4d0hPUK7f_1Zdhcs0zYWWzbD0D9f8WzK5EYNGj-ChJ4942KG9A_ds8xi2T_32-BP4NTlib8fvQjxpLqd66i7SwXKO5Lf-nNVPJI6K9IyjKdE-RpmoxbOV1hzbGvO2YV-vytmMDexshmOaC3DgLOMGJ10J1jm6tVt0AhGk8cYhDn94NW3zHg8x74TleGoXJVvVPHkK56Ph2eCY-bsXWEUZ34JVlVFlEpU6zZTRNZcmrbXQimAVWRgZJZW2qaEIG1rKSTJqjbmwaVTHmUmIszyDXtM2dhcwylJeJSo2Upay1opeQ6xJhlqVpRA8C-Bg9euL667ERkGpiUOo2EAogL0VLIX3s3nxxyoCeLNuJg9x2x5lY9tb6kMcNFaJCMMAnncorscRrsAZMcIAkjv4rju46tt3W5rp5bIKd8pd7X754v-f9Rq2yUyL8Un--SU8iJwghgsWqT3oLW5u7T4xmoV-5U31N4dM9w8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PD-%28L%291+Inhibitors+as+Monotherapy+for+the+First-Line+Treatment+of+Non-Small-Cell+Lung+Cancer+Patients+with+High+PD-L1+Expression%3A+A+Network+Meta-Analysis&rft.jtitle=Journal+of+clinical+medicine&rft.au=Majem%2C+Margarita&rft.au=Cobo%2C+Manuel&rft.au=Isla%2C+Dolores&rft.au=Marquez-Medina%2C+Diego&rft.date=2021-03-26&rft.issn=2077-0383&rft.eissn=2077-0383&rft.volume=10&rft.issue=7&rft_id=info:doi/10.3390%2Fjcm10071365&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2077-0383&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2077-0383&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2077-0383&client=summon